← Back to Search

MAT-PLUS "Helping Hands" for Opioid Addiction (MAT-PLUS Trial)

N/A

Waitlist Available

Led By Marc Fishman, MD

Research Sponsored by Potomac Health Foundations

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months

Awards & highlights

MAT-PLUS Trial Summary

This trial is testing a new approach to improving the delivery and effectiveness of XRNTX treatment for opioid use disorder - the MAT-PLUS intervention. The intervention includes XRNTX, initiated during an episode of inpatient/residential treatment and dosed monthly, which provides opioid receptor blockade, relapse prevention and overdose prevention; significant other engagement, which empowers family members or other designated concerned others, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; and assertive outreach, which incorporates frequent multi-channel outreach, in a model that specifically targets engagement and motivation for medication adherence.

Eligible Conditions

Opioid Addiction
Opioid Use Disorder

MAT-PLUS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean number of XRNTX doses within each group

Secondary outcome measures

Mean Number of days of opioid use

Percent Linkage to continuing care

Rate of opioid relapse during the study period

MAT-PLUS Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MAT-Plus InterventionExperimental Treatment1 Intervention

The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the "Helping Hands" approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing.

Group II: Treatment as UsualActive Control1 Intervention

TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Potomac Health FoundationsLead Sponsor

4 Previous Clinical Trials

340 Total Patients Enrolled

Marc Fishman, MDPrincipal InvestigatorMaryland Treatment Centers/PHF

4 Previous Clinical Trials

424 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research initiative still open to new participants?

"The clinical trial registry indicates that this medical research is actively recruiting participants. The study was initially posted on May 1, 2019 and the last update occurred on September 26, 2022."

Answered by AI

How many participants are currently being enrolled in this research program?

"Yes, the information provided on clinicaltrials.gov suggests that this trial is actively recruiting participants and has been since it was first listed in May 2019. Currently, 50 patients across 1 medical centre are required for the study's completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Treatment of Opioid Use: Medication Adherence Therapy

2019. "Treatment of Opioid Use: Medication Adherence Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03567356.